Abstract
One hundred Mycoplasma pneumoniae strains were isolated from pediatric patients from March 2008 to July 2009. Of 100 isolates, 90 (90%) were resistant to erythromycin (MICs >128 microg/mL for 88 strains and 64 microg/mL for 2 strains), azithromycin, and clarithromycin. Fluoroquinolones and tetracyclines maintain good activities against clinical M. pneumoniae isolates. Of 90 macrolide-resistant M. pneumoniae strains, 88 (98%) harbored an A-to-G transition mutation at position 2063 in 23S rRNA genes, and the remaining 2 showed either A2064G or A2063T mutation; the latter point mutation is newly discovered and reported. Ninety-three (93%) clinical isolates were classified into the P1 gene restriction fragment length polymorphism (RFLP) type I, and 7 (7%) were type II.
Copyright 2010 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Bacterial Agents / pharmacology*
-
Azithromycin / pharmacology
-
Bacterial Typing Techniques
-
Child
-
Child, Preschool
-
China
-
Clarithromycin / pharmacology
-
DNA Fingerprinting
-
Drug Resistance, Bacterial*
-
Erythromycin / pharmacology
-
Fluoroquinolones / pharmacology
-
Genotype
-
Humans
-
Macrolides / pharmacology*
-
Microbial Sensitivity Tests
-
Mycoplasma pneumoniae / classification
-
Mycoplasma pneumoniae / drug effects*
-
Mycoplasma pneumoniae / genetics
-
Mycoplasma pneumoniae / isolation & purification
-
Pneumonia, Mycoplasma / microbiology*
-
Point Mutation
-
Polymorphism, Restriction Fragment Length
-
RNA, Bacterial / genetics
-
RNA, Ribosomal, 23S / genetics
-
Tetracyclines / pharmacology
Substances
-
Anti-Bacterial Agents
-
Fluoroquinolones
-
Macrolides
-
RNA, Bacterial
-
RNA, Ribosomal, 23S
-
Tetracyclines
-
Erythromycin
-
Azithromycin
-
Clarithromycin